{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:45:48Z","timestamp":1774687548389,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"General Practice Research Foundation of the Central Denmark Region","award":["file no. 1-30-72-112-16"],"award-info":[{"award-number":["file no. 1-30-72-112-16"]}]},{"name":"Foundation for General Practice","award":["file no. A4105"],"award-info":[{"award-number":["file no. A4105"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"DOI":"10.1186\/s12875-025-02852-8","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:37:40Z","timestamp":1747287460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reasons for omitting anticoagulant treatment in patients with atrial fibrillation: an audit of patient records in general practice"],"prefix":"10.1186","volume":"26","author":[{"given":"Ina Gr\u00f8nkjaer","family":"Laugesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mygind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flemming","family":"Bro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"2","key":"2852_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1747493019897870","volume":"16","author":"G Lippi","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217\u201321. https:\/\/doi.org\/10.1177\/1747493019897870.","journal-title":"Int J Stroke"},{"key":"2852_CR2","doi-asserted-by":"publisher","first-page":"e077209","DOI":"10.1136\/bmj-2023-077209","volume":"385","author":"N Vinter","year":"2024","unstructured":"Vinter N, Cordsen P, Johnsen SP, et al. Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study. BMJ. 2024;385:e077209. https:\/\/doi.org\/10.1136\/bmj-2023-077209.","journal-title":"BMJ"},{"key":"2852_CR3","doi-asserted-by":"publisher","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8. https:\/\/doi.org\/10.1161\/01.str.22.8.983","DOI":"10.1161\/01.str.22.8.983"},{"issue":"12","key":"2852_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857\u201367. https:\/\/doi.org\/10.7326\/0003-4819-146-12-200706190-00007.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2852_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"issue":"36","key":"2852_CR6","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS). Eur Heart J. 2024;45(36):3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"issue":"4","key":"2852_CR7","doi-asserted-by":"publisher","first-page":"e034778","DOI":"10.1136\/bmjopen-2019-034778","volume":"10","author":"S Salmasi","year":"2020","unstructured":"Salmasi S, Loewen PS, Tandun R, et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open. 2020;10(4):e034778. https:\/\/doi.org\/10.1136\/bmjopen-2019-034778.","journal-title":"BMJ Open"},{"issue":"6","key":"2852_CR8","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/europace\/euab303","volume":"24","author":"M Grymonprez","year":"2022","unstructured":"Grymonprez M, Simoens C, Steurbaut S, et al. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. Europace. 2022;24(6):887\u201398. https:\/\/doi.org\/10.1093\/europace\/euab303.","journal-title":"Europace"},{"key":"2852_CR9","doi-asserted-by":"publisher","unstructured":"Komen JJ, Potteg\u00e5rd A, Mantel-Teeuwisse AK, et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace. 2021;23(11):1722\u201330. https:\/\/doi.org\/10.1093\/europace\/euab091.","DOI":"10.1093\/europace\/euab091"},{"issue":"SupplementA","key":"2852_CR10","doi-asserted-by":"publisher","first-page":"A42","DOI":"10.1093\/eurheartj\/suab152","volume":"24","author":"JM Farinha","year":"2022","unstructured":"Farinha JM, Jones ID, Lip GYH. Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation. Eur Heart J Supplements. 2022;24(SupplementA):A42\u201355. https:\/\/doi.org\/10.1093\/eurheartj\/suab152.","journal-title":"Eur Heart J Supplements"},{"issue":"5","key":"2852_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cjca.2023.01.020","volume":"39","author":"A Bhat","year":"2023","unstructured":"Bhat A, Karthikeyan S, Chen HHL, et al. Barriers to Guideline-Directed anticoagulation in patients with atrial fibrillation: new approaches to an old problem. Can J Cardiol. 2023;39(5):625\u201336. https:\/\/doi.org\/10.1016\/j.cjca.2023.01.020.","journal-title":"Can J Cardiol"},{"issue":"10","key":"2852_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12471-020-01424-y","volume":"28","author":"BA Mulder","year":"2020","unstructured":"Mulder BA, Ten Berg J, Ten Cate H, et al. Complex clinical scenarios with the use of direct oral anticoagulants in patients with atrial fibrillation: a multidisciplinary expert advisory board. Neth Heart J. 2020;28(10):504\u201313. https:\/\/doi.org\/10.1007\/s12471-020-01424-y.","journal-title":"Neth Heart J"},{"key":"2852_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.thromres.2021.10.025","volume":"208","author":"EA Gebreyohannes","year":"2021","unstructured":"Gebreyohannes EA, Salter SM, Chalmers L, et al. Reasons for non-adherence to thromboprophylaxis prescribing guidelines in atrial fibrillation in Western Australia: A qualitative descriptive study of general practitioners\u2019 views. Thromb Res. 2021;208:83\u201391. https:\/\/doi.org\/10.1016\/j.thromres.2021.10.025.","journal-title":"Thromb Res"},{"issue":"4","key":"2852_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/1474515118812252","volume":"18","author":"SD Pokorney","year":"2019","unstructured":"Pokorney SD, Bloom D, Granger CB, et al. Exploring patient-provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: results of the INFORM-AF study. Eur J Cardiovasc Nurs. 2019;18(4):280\u201388. https:\/\/doi.org\/10.1177\/1474515118812252.","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2852_CR15","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2147\/ppa.S463164","volume":"18","author":"BJW van de Steeg","year":"2024","unstructured":"van de Steeg BJW, Esselink AC, de Wit H, et al. Medication adherence to direct oral anticoagulants: extent and impact of side effects. Patient Prefer Adherence. 2024;18:1779\u201388. https:\/\/doi.org\/10.2147\/ppa.S463164.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"2852_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40271-016-0180-1","volume":"10","author":"EY Pandya","year":"2017","unstructured":"Pandya EY, Bajorek B. Factors affecting patients\u2019 perception on, and adherence to, anticoagulant therapy: anticipating the role of direct oral anticoagulants. Patient. 2017;10(2):163\u201385. https:\/\/doi.org\/10.1007\/s40271-016-0180-1.","journal-title":"Patient"},{"issue":"7","key":"2852_CR17","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.hlc.2019.11.022","volume":"29","author":"KL Rush","year":"2020","unstructured":"Rush KL, Burton L, Ollivier R, et al. Transitions in atrial fibrillation care: A systematic review. Heart Lung Circ. 2020;29(7):1000\u201314. https:\/\/doi.org\/10.1016\/j.hlc.2019.11.022.","journal-title":"Heart Lung Circ"},{"issue":"7","key":"2852_CR18","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/bcp.14691","volume":"87","author":"A Potteg\u00e5rd","year":"2021","unstructured":"Potteg\u00e5rd A, Olesen M, Christensen B, et al. Who prescribes drugs to patients: A Danish register-based study. Br J Clin Pharmacol. 2021;87(7):2982\u201387. https:\/\/doi.org\/10.1111\/bcp.14691.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"2852_CR19","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.3122\/jabfm.2012.02.110216","volume":"25","author":"KM Pedersen","year":"2012","unstructured":"Pedersen KM, Andersen JS, S\u00f8ndergaard J. General practice and primary health care in Denmark. J Am Board Fam Med. 2012;25(Suppl 1):S34\u20138. https:\/\/doi.org\/10.3122\/jabfm.2012.02.110216.","journal-title":"J Am Board Fam Med"},{"key":"2852_CR20","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/clep.S443473","volume":"15","author":"L Frost","year":"2023","unstructured":"Frost L, Joensen AM, Dam-Schmidt U, et al. The Danish atrial fibrillation registry: A multidisciplinary National pragmatic initiative for monitoring and supporting quality of care based on data retrieved from administrative registries. Clin Epidemiol. 2023;15:1259\u201372. https:\/\/doi.org\/10.2147\/clep.S443473.","journal-title":"Clin Epidemiol"},{"key":"2852_CR21","unstructured":"Population Figures: Statistics Denmark. 2024 [Available from: accessed 16 December 2024]. https:\/\/www.dst.dk\/en\/Statistik\/emner\/borgere\/befolkning\/befolkningstal"},{"issue":"2","key":"2852_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0168-8510(01)00201-9","volume":"59","author":"T Christiansen","year":"2002","unstructured":"Christiansen T. Organization and financing of the Danish health care system. Health Policy. 2002;59(2):107\u201318. https:\/\/doi.org\/10.1016\/s0168-8510(01)00201-9.","journal-title":"Health Policy"},{"issue":"2","key":"2852_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372. https:\/\/doi.org\/10.1378\/chest.09-1584.","journal-title":"Chest"},{"issue":"5","key":"2852_CR24","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010;138(5):1093\u2013100. https:\/\/doi.org\/10.1378\/chest.10-0134.","journal-title":"Chest"},{"issue":"5","key":"2852_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"key":"2852_CR26","volume-title":"Release 14. [program]","author":"Stata Statistical Software","year":"2015","unstructured":"Stata Statistical Software. Release 14. [program]. College Station, TX: StataCorp LP; 2015."},{"issue":"3","key":"2852_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/14017431.2012.673728","volume":"46","author":"TA Rix","year":"2012","unstructured":"Rix TA, Riahi S, Overvad K, et al. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J. 2012;46(3):149\u201353. https:\/\/doi.org\/10.3109\/14017431.2012.673728.","journal-title":"Scand Cardiovasc J"},{"issue":"11","key":"2852_CR28","doi-asserted-by":"publisher","first-page":"e012832","DOI":"10.1136\/bmjopen-2016-012832","volume":"6","author":"J Sundb\u00f8ll","year":"2016","unstructured":"Sundb\u00f8ll J, Adelborg K, Munch T, et al. Positive predictive value of cardiovascular diagnoses in the Danish National patient registry: a validation study. BMJ Open. 2016;6(11):e012832. https:\/\/doi.org\/10.1136\/bmjopen-2016-012832.","journal-title":"BMJ Open"},{"issue":"17","key":"2852_CR29","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","volume":"38","author":"IC Van Gelder","year":"2017","unstructured":"Van Gelder IC, Healey JS, Crijns H, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38(17):1339\u201344. https:\/\/doi.org\/10.1093\/eurheartj\/ehx042.","journal-title":"Eur Heart J"},{"key":"2852_CR30","doi-asserted-by":"publisher","first-page":"132921","DOI":"10.1016\/j.ijcard.2024.132921","volume":"422","author":"V De Sio","year":"2024","unstructured":"De Sio V, Gragnano F, Capolongo A, et al. Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): current evidence and open questions. Int J Cardiol. 2024;422:132921. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132921.","journal-title":"Int J Cardiol"},{"issue":"11","key":"2852_CR31","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1016\/j.jacep.2024.06.020","volume":"10","author":"G Peigh","year":"2024","unstructured":"Peigh G, Koehler J, Majumder S, et al. Associations between changes in maximum daily atrial fibrillation duration, ischemic stroke, and mortality. JACC Clin Electrophysiol. 2024;10(11):2394\u2013406. https:\/\/doi.org\/10.1016\/j.jacep.2024.06.020.","journal-title":"JACC Clin Electrophysiol"},{"issue":"10","key":"2852_CR32","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1253\/circj.cj-12-1036","volume":"76","author":"R Pisters","year":"2012","unstructured":"Pisters R, Lane DA, Marin F, et al. Stroke and thromboembolism in atrial fibrillation. Circ J. 2012;76(10):2289\u2013304. https:\/\/doi.org\/10.1253\/circj.cj-12-1036.","journal-title":"Circ J"},{"issue":"6","key":"2852_CR33","doi-asserted-by":"publisher","first-page":"e13489","DOI":"10.1111\/eci.13489","volume":"51","author":"WM Bezabhe","year":"2021","unstructured":"Bezabhe WM, Bereznicki LR, Radford J, et al. Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten-year follow-up. Eur J Clin Invest. 2021;51(6):e13489. https:\/\/doi.org\/10.1111\/eci.13489","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"2852_CR34","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.18553\/jmcp.2022.28.10.1161","volume":"28","author":"L Wirbka","year":"2022","unstructured":"Wirbka L, Ruff C, Haefeli WE, et al. A prediction model for nonpersistence or nonadherence to direct oral anticoagulants in hospitalized patients with atrial fibrillation. J Manag Care Spec Pharm. 2022;28(10):1161\u201372. https:\/\/doi.org\/10.18553\/jmcp.2022.28.10.1161.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"2852_CR35","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1055\/a-2161-0928","volume":"7","author":"SFB van der Horst","year":"2023","unstructured":"van der Horst SFB, de Vries TAC, Chu G, et al. Prevalence and predictors of nonadherence to direct oral anticoagulant treatment in patients with atrial fibrillation. TH Open. 2023;7(3):e270\u201379. https:\/\/doi.org\/10.1055\/a-2161-0928.","journal-title":"TH Open"},{"key":"2852_CR36","doi-asserted-by":"publisher","first-page":"e072953","DOI":"10.1136\/bmj-2022-072953","volume":"380","author":"M Johansson","year":"2023","unstructured":"Johansson M, Guyatt G, Montori V. Guidelines should consider clinicians\u2019 time needed to treat. BMJ. 2023;380:e072953. https:\/\/doi.org\/10.1136\/bmj-2022-072953.","journal-title":"BMJ"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-02852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-025-02852-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-02852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:37:43Z","timestamp":1747287463000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/s12875-025-02852-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2852"],"URL":"https:\/\/doi.org\/10.1186\/s12875-025-02852-8","relation":{},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the general ethical principles of good clinical research practice as outlined by the World Medical Association in the Declaration of Helsinki. The Central Denmark Region authorised the use of data from electronic patient records in general practice under Sect.\u00a046(2) of the Danish Health Act, thereby waiving the requirement for written patient consent (file no.: 1-45-70-29-22). Before data collection, a data processing agreement was signed with each included general practice clinic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"The authors declare no competing interests related to this manuscript. ELG has previously received speaker honoraria or consultancy fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Pfizer, Novo Nordisk, Lundbeck Pharma and Organon. He is engaged in clinical studies sponsored by AstraZeneca, Idorsia or Bayer and has received unrestricted research grants from Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}